According to EHA recommendations; patients with CML who discontinued TKI for less than one year and who do not have access to regular monitoring of CBC counts and BCR-ABL transcripts in time of COVID-19 pandemic are suggested to discuss with their doctors to restart TKI treatment6. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.